AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05073744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine hydrochloride injection or morphine hydrochloride injection is used for perioperative tumor ablation
Study NCT05073744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine hydrochloride injection is used for perioperative tumor ablation
Study NCT05646992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Allotransplantation
Description: Temporary allogenic uterus transplantation from a living donor with the goal of achieving pregnancy and delivering viable baby.
Study NCT05646992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Used as daily immunosuppression. Started at 3mg twice daily (PO) on post-operative Day 1, adjusted to achieve serum trough concentrations of 8-10ng/ml.
Study NCT05646992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imuran
Description: Used as daily immunosuppresion. 100 mg for total body weight less than 75 kg and 150 mg for total body weight greater than or equal to 75 mgs
Study NCT05998772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test
Description: Application of 82,5 g of glucose monohydrate solved in 300ml water
Study NCT05998772 — intervention group
Intervention type: OTHER
Intervention: Placebo Oral Glucose Tolerance Test
Description: Application of 125mg sucralose solved in 300ml water
Study NCT05082896 — intervention group
Intervention type: PROCEDURE
Intervention: Type of anesthesia choice
Description: Use of conscious sedation vs. general anesthesia
Study NCT05642273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris membrane
Description: oXiris membrane for 24h
Study NCT05642273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood tests
Description: Blood tests just after randomization (0 h) and at 24 h, 48 h and 7 days
Study NCT05642273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood tests
Description: Blood tests just after randomization (0 h) and at 24 h, 48 h and 7 days
Study NCT05597800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~* Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~* Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles).
Study NCT00047983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Canola oil
Study NCT00047983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Study NCT00047983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil emulsion
Study NCT05534464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Twenty grams of the deuterium (2H) - labelled skimmed milk powder mixed with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. Protein free cookies are served alongside to equal macronutrient composition with the other two protein sources.
Study NCT05534464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sorghum
Description: Twenty grams of the deuterium (2H) - labelled whole grain sorghum cooked with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference.
Study NCT05534464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black beans
Description: Twenty grams of the deuterium (2H) - labelled black beans cooked with water and mashed into a puree, will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. A carbohydrate drink is served alongside to equal macronutrient composition with the other two protein sources.
Study NCT03644706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADV7103
Description: Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
Study NCT03644706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules.
Study NCT05275751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPA1-inhibitor
Description: Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
Study NCT04064021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupunture
Description: Patient will receive 12 acupuncture treatments over 6 weeks (2x per week)
Study NCT05548868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E4W mobile app
Description: Eating for Wellness (E4W) is a mobile application that analyzes photos of meals taken by the user and determines the nutritional profile. Nutritional content is then directly transmitted to the dietitian.
Study NCT05548868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients will receive standard dietary counselling as part of the weight management program.
Study NCT05548868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Patients will receive standard dietary counselling as part of the weight management program.
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: Day 0; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: Day 28; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: Day 180; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: Day 0; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: Day 28; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: Day 180; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA vaccine manufactured by Pfizer or Moderna
Description: Day 0; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA vaccine manufactured by Pfizer or Moderna
Description: Day 28; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA vaccine manufactured by Pfizer or Moderna
Description: Day 180; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm inactivated COVID-19 vaccine
Description: Day 0; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm inactivated COVID-19 vaccine
Description: Day 28; intramuscular injection
Study NCT05308602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm inactivated COVID-19 vaccine
Description: Day 180; intramuscular injection
Study NCT05716854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD).
Study NCT05716854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimozide
Description: Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day.
Study NCT05716854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1)
Description: Subjects receive matching placebo for treatments.
Study NCT05716854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Subjects receive Moxifloxacin 800 mg orally once on day 1.
Study NCT05716854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobicistat
Description: Subjects receive Cobicistat 450 mg orally once on day 1.
Study NCT05716854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin and Cobicistat
Description: Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.
Study NCT05716854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2)
Description: Subjects receive matching placebo for treatments.
Study NCT06130891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive sensory motor relearning
Description: Cognitive Exercises:~* Orientation: Checking awareness of date, time, and weather.~* Attention: Tasks like connecting dots or spotting differences.~* Shape Sorting: Sorting objects by size, color, etc.~* Calculation Training: Counting money, beads, basic arithmetic.~* Memory: Recalling objects on a tray, numbers backward, word associations.~Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks.
Study NCT06130891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory motor relearning
Description: Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks.
Study NCT06130891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Relearning
Description: Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks.
Study NCT04662788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK cells/Combined Monoclonal Antibodies
Description: Each subject receive NK cells/Combined Monoclonal Antibodies
Study NCT05538767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: Treatment with Emodepside 30 mg
Study NCT05538767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400mg
Description: Treatment with Albendazole 400 mg
Study NCT05194267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS alters brain excitability using a weak electric field induced through two electrodes and could potentially improve symptoms of depression
Study NCT06011460 — intervention group
Intervention type: DRUG
Intervention: Clozapine
Description: Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5).~Age from 18 to 65 years old.
Study NCT06385691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myDIET software tool
Description: The tool is based on self-questionnaires completed by the patient. They are mainly filled in using visual analogue scales (from 0-10) or grades of symptoms/toxicities (Grades 0 to 4), based on the CTCAE V5. These scales will cover the following themes: food intake, weight changes, digestive symptoms, taste disorders, pain and fatigue. The system will be able to monitor data changes and the response given will be adapted according to the severity of symptoms:~* No signs of seriousness: general prevention or treatment documents/advice: toxicity management, nutritional advices targeted on symptoms, on digestive problems, on appropriate physical activity.~* Presence of signs of seriousness: action to be taken and alert to the coordinating nurse, oncologist or dietician.~In case of an alert, the coordinating nurse will call the patient back and either manage the symptom, schedule a nutritional consultation to initiate nutritional management, or refer the patient to the oncologist.
Study NCT05062824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Feed
Description: Baby Feed web portals can (1) Quickly and easily evaluate infant diet using a validated Infant Food Frequency Questionnaire (infant FFQ) developed by our group14. \[Parental FFQ portal\]; (2) Provide automatic results to healthcare professionals on nutrients and foods/beverages consumed above or below the recommended levels to discuss with parents for improving the infant's diet. Also, to provide recommendations for amounts of foods/beverages that the infant should be consuming by age \[Clinician Portal\]; (3) Give online access to parents to these diet recommendations to implement at home, with an easy tracking component \[Parent's Portal\].
Study NCT05661630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDUCATION AND COUNSELING WITH EX-PLISSIT MODEL
Description: In addition to the routine procedure, the women in the experimental group of the research will be given sexual education and counseling with the EX-PLISSIT model. The steps to be followed in accordance with this model are as follows; Session 1 Permission Limited Information The Specific Suggestions The IT-Intensive Therapy Session 2 At the beginning of the interview, the data forms will be reapplied, and then the homework given in the first session will be discussed. The information that the patient needs in line with his questions will be given within the steps of the Ex-PLISSIT model, within the steps of allowing, limited information, special recommendations and, if necessary, intensive therapy.~Session 3 At the beginning of the interview, the data forms will be applied for the last time and the patient's questions, if any, will be answered and the session will be ended.
Study NCT05990192 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Niraparib oral capsule
Description: Niraparib used following SBRT treatment until disease progression
Study NCT05990192 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Description: SBRT may be delivered using a specialist SBRT platform, such as CyberKnife or with a linear accelerator with SBRT capabilities.
Study NCT05595564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Description: A previous application of photobiomodulation therapy was offered or not, for possible performance enhancement.
Study NCT05595564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation therapy
Description: A previous application of photobiomodulation therapy was offered or not, for possible performance enhancement.
Study NCT04788225 — intervention group
Intervention type: OTHER
Intervention: Balance assessment
Description: Static balances will be measured with the Biodex-BioSway 950-462 static balance device according to 3 different standard test procedures (Postural Stability Test, Stability Limit Test and Modified Sensori Organization Test) in single foot stance and double foot stance.~Dynamic balances will be evaluated with the Y balance test.
Study NCT04788225 — intervention group
Intervention type: OTHER
Intervention: Functionality assessment
Description: Functionality will be evaluated with the Lower Extremity Functional Scale and AOFAS (American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale)
Study NCT04788225 — intervention group
Intervention type: OTHER
Intervention: Performance assessment
Description: Performance evaluation will be made with a single leg jump test and time up and go test.
Study NCT04788225 — intervention group
Intervention type: OTHER
Intervention: ROM assessment
Description: Range of motion (ROM) of the ankle will be measured with an electrogonyometer in dorsi-plantar flexion.
Study NCT06547242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxin
Description: Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
Study NCT06547242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin
Description: Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
Study NCT05447767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KIT BMAC AND at-SVF FIDIA
Description: intra-articular infiltration or intra-articular and intra-osseous infiltration
Study NCT06041425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: The patients were given 0.1mg/kg oxycodone 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
Study NCT06041425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
Study NCT05878821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Shockwave therapy session once a week for month 1000shock per session
Study NCT04643418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPB-1734
Description: Administered once daily in a 21-day cycle
Study NCT04751773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Perioperative exercise training
Study NCT05451433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii 250 MG
Description: Normagut capsule twice a day
Study NCT05451433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule twice a day
Study NCT05170503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg iv drip. Qd D1 + Oxaliplatin 130/m2 iv drip. Qd D1 + Tegafur (Gimeracil and Oteracil Potassium Capsules) \[40mg/m2 if BSA \<1.25m2, 50mg/m2 if BSA ≥1.25m2 \& \<1.5m2, 60mg/m2 if BSA ≥1.5m2\] po. Bid D1-14 for three cycles
Study NCT05487287 — intervention group
Intervention type: DEVICE
Intervention: Kinematic computational analysis of the hand (Leap Motion device)
Description: Kinematic computational analysis exercises:~1. Finger extension~2. Wrist extension~3. Finger separation~4. Finger clamp
Study NCT05269212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care trajectory
Description: Usual care after Spinal Cord Stimulation implantation
Study NCT05269212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A biopsychosocial rehabilitation program
Description: A personalized biopsychosocial rehabilitation program specifically targeting return to work.
Study NCT05811052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital Release Technique
Description: The suboccipital release technique was applied to the participants in the experimental group by an experienced practitioner who had received osteopathy training. The individual lay in the supine position, and the practitioner applied the relaxation technique by placing his hands on the patient's nape-atlantooccipital joint. The application was continued until the relaxation of the muscles under the hand of the practitioner.
Study NCT05811052 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Suboccipital Release
Description: The participants in the control group were given a sham application by touching the hands of the therapist on the nape of the neck and waiting for a while.
Study NCT05964114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Initial dosing based on (a combinations of) pharmacokinetic models tailored to the individual patient. Dose adjustment starting dose (within registered dosing range).
Study NCT05596500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry-protein gel
Description: Sport gel with blueberry extract and plant protein.
Study NCT05596500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry gel
Description: Sport gel with blueberry extract only.
Study NCT05596500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sport gel without the blueberry extract polyphenols and without protein.